ArticleCancer management and research2026
Advancing Precision Medicine in Non-Small Cell Lung Cancer Diagnostics in a Southeast Asian Country.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Next-generation sequencing (NGS) has transformed molecular diagnostics and precision oncology by enabling broad genomic profiling and informed treatment selection for non-small cell lung cancer (NSCLC). However, adoption in Southeast Asia remains limited, particularly in public healthcare settings. This study aimed to assess the landscape of NGS testing for NSCLC in Malaysia, identify barriers, and explore strategies clinicians use to improve patient access. Patients and Methods: A descriptive, cross-sectional survey comprising 18 questions was distributed to clinical oncologists and respiratory physicians across Malaysia over an eight-week period. The survey collected data on clinical experience with NGS, testing practices, perceived barriers, and access strategies. Descriptive statistics were used for analysis, and associations between healthcare sectors (public vs private) and NGS usage frequency were evaluated using the Chi-square test. Results: Seventy-one clinicians participated - 67.6% clinical oncologists and 32.4% respiratory physicians. Private hospitals had the highest NGS uptake (38.5% testing all NSCLC patients), with the lowest in Ministry of Health (MoH) institutions (8.3%) (p<0.0001). Among oncologists, 45.8% used NGS for all or nearly all patients. For respiratory physicians, 35.3%, mainly from MoH, used it most of the time. NGS results were more frequently available in private referrals. Most private clinicians (84.6%) rated NGS accessibility as excellent. Key barriers included cost of testing and therapies, limited availability, long turnaround times, insufficient tissue, and unclear guidelines. Strategies to improve access included industry-subsidized programs, insurance coverage, and clinical trial enrolment. Conclusion: NGS adoption for NSCLC in Malaysia varies significantly across healthcare settings. Public hospitals face substantial barriers, particularly related to cost and access to testing and therapies. Addressing these challenges will require coordinated efforts across policy, infrastructure, clinician training, and public-private partnerships. This study offers key insights into the Malaysian NGS landscape and supports broader access to precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.